Bioactive Cyclization Optimizes the Affinity of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Peptide Inhibitor-Reference-Cited by-同舟云学术

Bioactive Cyclization Optimizes the Affinity of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Peptide Inhibitor

Published:2020-12-23 Issue:5 Volume:64 Page:2523-2533
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Tombling Benjamin J.¹^ORCID,Lammi Carmen²^ORCID,Lawrence Nicole¹^ORCID,Gilding Edward K.¹^ORCID,Grazioso Giovanni²^ORCID,Craik David J.¹^ORCID,Wang Conan K.¹^ORCID

Affiliation:

1. Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, Qld 4072, Australia

2. Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via L. Mangiagalli 25, 20133 Milan, Italy

Funder

National Health and Medical Research Council

Australian Research Council

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01766

Reference62 articles.

1. The Future of Peptide-based Drugs